EGFR and non-small cell lung carcinoma: On the basis of these findings, osimertinib was assessed as a first-line treatment for EGFR mutation–positive NSCLC in comparison to a first-generation EGFR TKI (gefitinib or erlotinib) in the FLAURA trial, which demonstrated a significant improvement in PFS with osimertinib [14].